• Curaleaf outlined plans to buy Aurora Cannabis in a cash-and-stock deal valued at US $4 per Aurora share.
• Consideration set at 0.35 Curaleaf subordinate voting shares, cash of US $0.75 for each Aurora share.
• Terms imply a 45% premium to Aurora’s 30-day VWAP of US $2.75.
• Value capped at US $5 per share if Curaleaf’s 20-day VWAP rises sharply, with the share ratio adjusted.
• Curaleaf targets at least US $40 million in annual cost synergies, citing complementary EU-GMP capacity and international distribution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curaleaf Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608110825PR_NEWS_USPR_____NE23688) on August 11, 2026, and is solely responsible for the information contained therein.